Ligand Pharmaceuticals (LGND) Net Cash Flow Growth (3y) (2013 - 2026)
Ligand Pharmaceuticals (LGND) Net Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | -50.33% |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn | 38.47% |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn | 33.37% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | -29.82% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - | - |
| 10 | Ligand Pharmaceuticals | 6.02 Bn | 5.24 Bn | 48.45 Mn | -49.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.89% |
| Dec 31, 2025 | -4.03% |
| Sep 30, 2025 | 294.78% |
| Jun 30, 2025 | 59.69% |
| Mar 31, 2025 | -77.43% |
| Dec 31, 2024 | 66.55% |
| Sep 30, 2024 | 216.47% |
| Jun 30, 2024 | -46.37% |
| Mar 31, 2024 | 54.97% |
| Dec 31, 2023 | 26.15% |
| Sep 30, 2023 | -26.52% |
| Jun 30, 2023 | -193.68% |
| Mar 31, 2023 | -1.79% |
| Dec 31, 2022 | 31.33% |
| Sep 30, 2022 | 71.05% |
| Jun 30, 2022 | -26.73% |
| Mar 31, 2022 | 28.79% |
| Dec 31, 2021 | 53.64% |
| Sep 30, 2021 | -43.16% |
| Jun 30, 2021 | -28.09% |